Page 35 - EASL POSTGRADUATE COURSE
P. 35
References (*required reading)
[1] Schwimmer JB, Deutsch R, Kahen T, et al. Prevalence of fatty liver in children and adolescents.
Pediatrics 2006;118:1388-1393.
[2] Dongiovanni P, Anstee QM, Valenti L. Genetic predisposition in NAFLD and NASH: impact on
severity of liver disease and response to treatment. Curr Pharm Des 2013;19:5219-5238.
[3] Nobili V, Donati B, Panera N, et al. A 4-polymorphism risk score predicts steatohepatitis in
children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2014;58:632-636. *
[4] Alisi A, Feldstein AE,Villani A, et al. Pediatric nonalcoholic fatty liver disease: a multidisciplinary
approach. Nat Rev Gastroenterol Hepatol 2012;9:152-161.
[5] Vajro P, Lenta S, Socha P, et al. Diagnosis of nonalcoholic fatty liver disease in children and
adolescents: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol
Nutr 2012;54:700-713. *
[6] Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol
2010;7:195-203.
[7] Alkhouri N, De Vito R, Alisi A, et al. Development and validation of a new histological score for
pediatric non-alcoholic fatty liver disease. J Hepatol 2012;57:1312-1318. *
[8] Nobili V, Svegliati-Baroni G, Alisi A, et al. A 360-degree overview of paediatric NAFLD: recent
insights. J Hepatol 2013;58:1218-1229.
[9] Socha P, Horvath A, Vajro P, et al. Pharmacological interventions for nonalcoholic fatty liver
disease in adults and in children: a systematic review. J Pediatr Gastroenterol Nutr 2009;48:587-
596.
[10] Della Corte C, Liccardo D, Ferrari F, et al. Current pharmacotherapy for treating pediatric
nonalcoholic fatty liver disease. Expert Opin Pharmacother 2014;15:2501-2511. *
The International Liver Congress™ 2015 • Vienna, Austria • April 22–23, 2015 35
[1] Schwimmer JB, Deutsch R, Kahen T, et al. Prevalence of fatty liver in children and adolescents.
Pediatrics 2006;118:1388-1393.
[2] Dongiovanni P, Anstee QM, Valenti L. Genetic predisposition in NAFLD and NASH: impact on
severity of liver disease and response to treatment. Curr Pharm Des 2013;19:5219-5238.
[3] Nobili V, Donati B, Panera N, et al. A 4-polymorphism risk score predicts steatohepatitis in
children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2014;58:632-636. *
[4] Alisi A, Feldstein AE,Villani A, et al. Pediatric nonalcoholic fatty liver disease: a multidisciplinary
approach. Nat Rev Gastroenterol Hepatol 2012;9:152-161.
[5] Vajro P, Lenta S, Socha P, et al. Diagnosis of nonalcoholic fatty liver disease in children and
adolescents: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol
Nutr 2012;54:700-713. *
[6] Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol
2010;7:195-203.
[7] Alkhouri N, De Vito R, Alisi A, et al. Development and validation of a new histological score for
pediatric non-alcoholic fatty liver disease. J Hepatol 2012;57:1312-1318. *
[8] Nobili V, Svegliati-Baroni G, Alisi A, et al. A 360-degree overview of paediatric NAFLD: recent
insights. J Hepatol 2013;58:1218-1229.
[9] Socha P, Horvath A, Vajro P, et al. Pharmacological interventions for nonalcoholic fatty liver
disease in adults and in children: a systematic review. J Pediatr Gastroenterol Nutr 2009;48:587-
596.
[10] Della Corte C, Liccardo D, Ferrari F, et al. Current pharmacotherapy for treating pediatric
nonalcoholic fatty liver disease. Expert Opin Pharmacother 2014;15:2501-2511. *
The International Liver Congress™ 2015 • Vienna, Austria • April 22–23, 2015 35
